A Tibet Haisco Pharmaceutical Co. Ltd. patent describes new phosphodiesterase PDE4B inhibitors potentially useful for the treatment of cancer, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.
Mast/stem cell growth factor receptor KIT is a receptor tyrosine kinase that plays a key role in mast cell differentiation, proliferation, survival and activation.
Max Biopharma Inc. and Metaba LLC are collaborating to study the effects of oxysterol drug candidates that target metabolic dysfunction-associated steatohepatitis (MASH, formerly nonalcoholic steatohepatitis or NASH), idiopathic pulmonary fibrosis, chronic inflammation, and atherosclerosis on metabolic processes.
Researchers from the Peking University Health Science Center have developed a murine model of RSV infection based on the knockout of the Rag2 gene using CRISPR/Cas9 (Rag2-/- mice).
On the verge of top-line data from its phase IIb trial with oral small-molecule CC chemokine receptor 4 (CCR4) antagonist zelnecirnon in atopic dermatitis (AD), due around the middle of this year, Rapt Therapeutics Inc. said the U.S. FDA has imposed a clinical hold on that study with the otherwise promising drug, also known as RPT-193, in AD as well as the phase IIa trial with the same compound in asthma.
Chiesi Farmaceutici SpA has detailed new discoidin domain-containing receptor DDR1 and DDR2 inhibitors reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
Intellia Therapeutics Inc. and Recode Therapeutics Inc. have established a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis.